Profil bibliographique

Vithika Suri

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

106Publications signalées

2039Citations signalées

3Affiliations récentes

Institutions déclarées

Evorx (United States)Xencor (United States)Gilead Sciences (United States)

Domaines associés

Hepatitis C virus researchHepatitis B Virus StudiesLiver Disease Diagnosis and TreatmentHIV/AIDS drug development and treatmentHepatitis Viruses Studies and Epidemiology

Publications récentes

2025 conference-abstractOpenAlex

Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)

S. Pal, Randy F. Sweiss, Ritesh R. Kotecha, Karie Runcie et autres

2 citationsMolecular Cancer Therapeutics

Accès ouvert 2025 articleOpenAlex

17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433)

Chet Bohac, Sumanta Pal, Randy F. Sweis, Ritesh R. Kotecha et autres

2 citationsThe Oncologist

2025 articleOpenAlex

Safety and efficacy of tenofovir alafenamide in preventing hepatitis B virus recurrence after liver transplantation in patients with chronic kidney disease maintained on tenofovir disoproxil fumarate: Results from a phase 2 randomized trial

Edward Gane, Rica Dagooc, Dominic Ray-Chaudhuri, Vithika Suri et autres

0 citationsAmerican Journal of Transplantation

2025 articleOpenAlex

Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study

Regino P. González‐Peralta, Jessica Wen, Winita Hardikar, Wikrom Karnsakul et autres

5 citationsThe Lancet Child & Adolescent Health

Accès ouvert 2024 articleOpenAlex

Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B

David Z. Pan, Cameron M. Soulette, Abhishek Aggarwal, Dong Han et autres

17 citationsGut

Accès ouvert 2024 articleOpenAlex

Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide

Marı́a Buti, Heiner Wedemeyer, Soo Aleman, Vladimir Chulanov et autres

23 citationsJournal of Hepatology

Accès ouvert 2024 articleOpenAlex

Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation

Zhi Ming Xu, Gnimah Eva Gnouamozi, Sina Rüeger, Patrick R. Shea et autres

2 citationsThe American Journal of Human Genetics

Accès ouvert 2024 articleOpenAlex

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

Lena Allweiss, Annika Volmari, Vithika Suri, Jeffrey J. Wallin et autres

47 citationsJournal of Hepatology

2023 conference-abstractOpenAlex

S1617 Elevations in Total Serum Bile Acids During Bulevirtide Treatment Show No Association With Adverse Events of Interest in Patients With Chronic Hepatitis Delta: An Integrated Safety Analysis of 48-Week Data

Pietro Lampertico, Soo Aleman, Tarik Asselah, Adrian Streinu‐Cercel et autres

0 citationsThe American Journal of Gastroenterology

2023 articleOpenAlex

Efficacy and safety of bulevirtide monotherapy given at 2-mg or 10-mg dose level once daily for treatment of chronic hepatitis delta: Week 48 primary endpoint results from a Phase 3 randomized, multicenter, parallel design study

Heiner Wedemeyer, Katja Deterding, Soo Aleman, Maurizia Rossana Brunetto et autres

1 citationZeitschrift für Gastroenterologie

Accès ouvert 2023 articleOpenAlex

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study

Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn Jae Lee et autres

10 citationsThe Korean Journal of Internal Medicine

Accès ouvert 2023 articleOpenAlex

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank et autres

235 citationsNew England Journal of Medicine

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.